 |
| Company Name |
Zeria Pharmaceutical Co., Ltd. (Zeria Shinyaku Kogyo K.K.) |
| Headquarters |
10-11, Nihonbashi Kobuna-cho, Chuo-ku, Tokyo 103-8351 Tel. 03-3663-2351 |
| Established |
December 1955 |
| President & CEO |
Sachiaki Ibe |
| Business Activities |
1) Manufacture, sales, import and export of pharmaceuticals,
non-pharmaceutical products, veterinary pharmaceuticals,
agricultural chemicals, industrial chemicals and reagents; 2) Manufacture,
sales, import and export of cosmetics, health foods, alcoholic beverages,
carbonated beverages, food additives, livestock feed, hygienic goods,
medical devices, health equipment, hygiene facilities and equipment,
beauty appliances, measuring equipment, analytical equipment; and 3)
Activities related to the items described in 1) and 2) |
| Paid-in Capital |
¥6,593,398,500 |
| No. of Employees |
1,287 (consolidated, as of March 31, 2011) |
| Board of Directors |
| President & CEO |
 |
Sachiaki Ibe |
| Senior Managing Director |
Takeshi Saito, Hirokazu Endo, Shigeya Furuhata |
| Managing Directors |
Mitsuhiro Tago, Mikio Kan, Shigeru Moriyama |
| Directors of the Board |
Akira Ohno, Yasunori Nagatani, Hiroshi Ono, Makoto Kishimoto, Yoshihiro Hiraga, Nobuhito Hashimoto, Katsuyuki Ishii, Hiroki Kato, Hidekazu Yokote |
Standing Statutory
Auditors |
Masahiko Hanada, Koujirou Takami |
| External Auditors |
Tetsuo Komori, Yukiko Naka |
|
|
|
|
 |
| Dec.1955 |
Zeria Yakusho Kenkyusho Co., Ltd. is established
in Tokyo (capital: ¥3 million). |
| Dec.1964 |
Launches Chondroitin ZS Tablets, a
remedy for arthralgia and lumbalgia. |
| Aug.1967 |
Launches Hi Jelly B,
a nutrient tonic. |
| May 1969 |
Launches Marzulene-S Granules, an
anti-inflammatory anti-ulcerant. |
| May 1970 |
Changes name to Zeria Pharmaceutical Co., Ltd. |
| Apr.1975 |
Saitama Plant starts operations. |
| Jan.1978 |
Launches Hi Jelly Powder,
a royal jelly-containing
pharmaceutical for fatigue. |
| Mar.1979 |
Launches New Hepalyse,
a remedy for physical
fatigue and exhaustion. |
| Oct.1983 |
Establishes Central Research Laboratory
in Saitama. |
| Mar.1986 |
Develops and launches Avitene, an absorbable
topical hemostat in-licensed from
U.S.-based Alcon Laboratories, Inc. |
| Nov.1987 |
Launches WithOne, a herbal laxative. |
| Nov.1988 |
Tsukuba Plant starts operations. |
| Sep.1990 |
Launches Acinon Capsules 150, an anti-ulcerant
in-licensed from U.S.-based Eli Lilly and Company
and co-developed with Eli Lilly Japan K.K. |
| Sep.1991 |
Launches Ancer 20 injection,
an anti-leukopenia after radiotherapy. |
| Sep.1993 |
Launches Peon Tablets 80, an oral non-steroidal
anti-inflammatory co-developed with
Nippon Chemiphar Co., Ltd. |
| Apr.1994 |
Launches Landel Tablets 10/20, an long-acting
calcium channel blocker co-developed with
Nissan Chemical Industries, Ltd. |
| Oct.1994 |
Launches Promac 15%,
a zinc containing anti-ulcerant. |
| Feb.1996 |
Launches New Hepalyse Plus, a remedy
for physical fatigue and exhaustion. |
| Mar.1998 |
Launches Aposty Lotion, a dermatological
product for disinfecting skin. |
| Dec.1998 |
On December 22, listed on the Second Section of
the Tokyo Stock Exchange
Introduces new company logo and symbol mark. |
| Feb.1999 |
Started a new distribution system outsourced to
ITOCHU Corporation and its affiliate Superlex Co., Ltd. |
| Mar.2000 |
On March 1, listed on the First Section of
the Tokyo Stock Exchange. |
| Mar.2001 |
Launches Royal Jelly Peach Flavor Drink Sugarless,
a quasi-drug nutrient tonic. |
| Jul.2002 |
Concludes a basic agreement with Yamanouchi Pharmaceutical Co., Ltd.
(currently Astellas Pharma Inc.) regarding the development
and marketing of Z-338, a gastroprokinetic agent. |
| Feb.2004 |
Concludes a licensing agreement with Tillotts Pharma AG
in Switzerland for the development, manufacturing
and marketing rights to Asacol for IBD in Japan. |
| Jun.2005 |
Launches Acinon Z, a remedy
for gastrointestinal diseases
(Rx-to-OTC switched drug). |
| Jul.2005 |
Launches New Hepalyse Drink, a nutrient tonic
for physical fatigue and exhaustion. |
| Mar.2006 |
Sales of Chondroitin range
of products reach ¥5 billion. |
| Jul.2006 |
Launches Promac D Tablets 75,
a zinc containing anti-ulcerant. |
| Nov.2006 |
Expands Tsukuba Plant
(second phase construction). |
| Jun.2007 |
Concludes an agreement with Kyowa Hakko Kogyo Co., Ltd.
(currently Kyowa Hakko Kirin Co., Ltd.) regarding
co-development and co-marketing Z-206 (Asacol),
a treatment for IBD. |
| Jun.2007 |
Launches Visiclear Tablets, an oral bowel cleansing
agent for colonoscopy. |
| Nov.2007 |
Launches Acinon Tablets 75mg and 150mg,
a histamine H2 receptor antagonist. |
| Mar.2008 |
Concludes an agreement with Astellas Pharma regarding
the domestic co-development and co-marketing of Z-338,
a treatment for functional dyspepsia. |
| Jun.2008 |
TV commercials for Chondroitin ZS Tablets start. |
| Oct.2008 |
Acquires IONA INTERNATIONAL CORPORATION
and makes it a wholly owned subsidiary. |
| Feb.2009 |
Launches EnergyCan, Japan's
first quasi-drug nutrient tonic
packaged in an aluminum can. |
| Sep.2009 |
Acquires Tillotts Pharma AG
and makes it a wholly
owned subsidiary. |
| Dec.2009 |
Launches ulcerative colitis agent Asacol Tablets 400mg. |
| Jul.2010 |
TV commercials for New Hepalyse Drink start. |
| Sep.2010 |
Acquires Biofac Esbjerg A/S and makes it a subsidiary. |
|
|